Skip to search formSkip to main contentSkip to account menu

brivanib alaninate

The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

BMS 582664
Receptor Tyrosine Kinase Inhibition

Broader (1)

brivanib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Controlling the chemical stability of a moisture-sensitive drug product through monitoring and identification of coating process microenvironment.
2014
2014
Quality by design development of brivanib alaninate tablets: degradant and moisture control strategy.
2012
2012
Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal…
386 Background: The anti-EGFR monoclonal antibody CET has improved survival in pts with MET, chemotherapy refractory, K-RAS wild… 
2011
2011
Metabolism and Disposition of [14C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans
Brivanib [(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2,4]triazin-6-yloxy)propan-2-ol, BMS-540215] is a… 
2009
2009
Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate
PurposeBrivanib alaninate is a prodrug of brivanib (BMS-540215), a potent oral VEGFR-2 inhibitor and is currently in development… 
2008
2008
Correlation of FGF2 tumor expression with tumor response, PFS, and changes in plasma pharmacodynamic (PD) markers following treatment with brivanib alaninate, an oral dual inhibitor of VEGFR and FGFR…
3506 Background: Many tumors express the FGFR ligand FGF2, and increased levels of FGF are correlated with poor prognosis in pts… 
2007
2007
A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK…
3559 Background: Brivanib is an oral prodrug of BMS-540215, a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling. Part A… 
Highly Cited
2005
Highly Cited
2005
Spontaneously formed vesicles of sodium N-(11-acrylamidoundecanoyl)-glycinate and L-alaninate in water.
Two N-acyl amino acid surfactants, sodium N-(11-acrylamidoundecanoyl)-glycinate (SAUG) and L-alaninate (SAUA), were synthesized… 
2004
2004
Combination of cyclodextrins and polymeric surfactants for chiral separations
A cyclodextrin‐modified micellar electrokinetic chromatography (CD‐MEKC) method was applied to the enantioseparation of three… 
1990
1990
Thiol-containing cross-linking agent with enhanced steric hindrance.
Ricin A chain immunotoxins disulfide cross-linked with conventional, sterically unhindered reagents have unsatisfactorily short… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)